沙利度胺1 vs 2 mg/kg/d治疗输血依赖型地中海贫血的非劣效性试验
该前瞻性随机开放标签多中心试验在印度4个中心比较沙利度胺1 mg/kg/d与2 mg/kg/d对≥12岁输血依赖型地中海贫血患者的疗效与安全性。主要终点第24周输血需求减少率在1 mg/kg/d组显著更高(67.1% vs 50.0%,p=0.012),总体应答率58.5%,提示低剂量非劣效且安全性可接受。
要点
- 沙利度胺1 mg/kg/d组第24周总体应答率显著高于2 mg/kg/d组(67.1% vs 50.0%,p=0.012)。
- 总体应答率58.5%,良好应答20.5%、中度应答37.8%、无应答41.6%,9例(5.6%)达输血独立。
- 因毒性停药者占10.6%,不良事件多为1级,低剂量方案在资源有限地区可行。
核心结论
- 沙利度胺1 mg/kg/d在减少输血依赖型地中海贫血患者输血负担方面非劣效于2 mg/kg/d,且安全性可接受。
研究设计与样本
- 前瞻性、随机、开放标签、多中心临床试验,在印度4个中心开展。
- 纳入≥12岁输血依赖型地中海贫血患者188例,每组94例,82.4%完成第24周评估。
- 比较沙利度胺1 mg/kg/d(组1)与2 mg/kg/d(组2),主要终点为第24周输血需求减少程度。
主要发现
- 总体应答率58.5%,组1显著高于组2(67.1% vs 50.0%,p=0.012)。
- 良好应答、中度应答、无应答分别占20.5%、37.8%、41.6%,9例(5.6%)达输血独立。
- 良好应答者中71.8%在12周内出现临床获益,中度应答者100%在12周内出现获益。
- 第72周持续应答率在组1和组2初始应答者中分别为49%和57.5%。
- 不良事件多为1级,10.6%参与者因毒性需停药。
关键数值与推荐
- 应答分类:良好为输血需求减少>50%,中度为25-50%,无应答为<25%。
- 第24周总体应答率58.5%,组1为67.1%,组2为50.0%(p=0.012)。
- 第72周持续应答率:组1为49%,组2为57.5%。
- 因毒性停药率10.6%。
临床怎么用
- 低剂量沙利度胺(1 mg/kg/d)可作为资源有限地区输血依赖型地中海贫血的可行治疗选择。
- 治疗中需每4周进行安全性评估,关注毒性所致停药。
- 应答者可在第25-72周逐步减量以评估应答可持续性。
局限性
- 开放标签设计可能引入偏倚。
- 仅82.4%完成第24周评估,存在数据缺失。
- 随访至第72周,长期疗效与安全性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thalidomide has emerged as a fetal hemoglobin-inducer with potential to reduce transfusion burden in transfusion-dependent thalassemia (TDT). However, optimal dosing remains undefined A prospective, randomized, open-label, multicentric clinical trial was conducted at four centres in India to compare efficacy and safety of thalidomide at 1 mg/kg/day (Group 1) versus 2 mg/kg/day (Group 2) in patients with TDT aged ≥12 years. The primary endpoint was reduction in transfusion requirement at week 24, categorized as good (>50%), moderate (25-50%), or no (<25%) response. Responders underwent stepwise dose tapering during weeks 25-72 to evaluate response sustainability. Safety assessments were performed every 4 weeks. Of 188 enrolled patients (94 per group), 82.4% completed the week-24 evaluation. The overall response rate (ORR) was 58.5%, significantly higher in Group 1 than Group 2 (67.1% vs 50.0%, p=0.012). Good, moderate, and no response were observed in 20.5%, 37.8%, and 41.6% of patients, respectively, with transfusion independence in 9 patients (5.6%). Clinical benefit was observed within 12 weeks in 71.8% of good responders and 100% moderate responders. Sustained response at week 72 was seen in 49% and 57.5% of initial responders in Groups 1 and 2, respectively. Adverse effects were mostly grade 1; drug discontinuation due to toxicity was required in 10.6 % participants. These findings suggest that Thalidomide at 1 mg/kg/day was non-inferior to 2 mg/kg/day in reducing transfusion burden in patients with TDT, with an acceptable safety profile. Low-dose thalidomide appears to be a feasible treatment option in resource-limited settings. ICMR trial registry (Trial no. CTRI/2022/05/042781).
引用
- Kakkar S, Mahajan A, Sharma RA, et al. Efficacy and safety of thalidomide (1 vs 2 mg/kg/d) in transfusion-dependent thalassemia: A Non-Inferiority Trial. Blood Adv. 2026. PMID: 42679337. doi:10.1182/bloodadvances.2025019459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。